Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Zentalis Pharmaceuticals, Inc.
Market Cap
$190.07M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$189.11M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$182.60M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$198.33M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
99.54%
5Y Avg
99.69%
Market Cap
$180.47M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$179.75M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
16.67%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | $190.07M | 0.00% | 0.00% | 0.00% | 0.00% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $189.11M | 0.00% | 0.00% | 0.00% | 0.00% |
| RxSight, Inc. (RXST)vs › | $192.49M | 77.50% | 73.66% | 62.80% | 47.13% |
| Surrozen, Inc. (SRZN)vs › | $197.18M | 84.56% | 92.28% | 64.60% | 43.07% |
| AN2 Therapeutics, Inc. (ANTX)vs › | $182.60M | 0.00% | 0.00% | 0.00% | 0.00% |
| Exagen Inc. (XGN)vs › | $197.87M | 58.64% | 58.89% | 55.18% | 56.44% |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $198.33M | 100.00% | 100.00% | 99.54% | 99.69% |
| Canton Strategic Holdings Inc (CNTN)vs › | $180.47M | 0.00% | 0.00% | 0.00% | 0.00% |
| Compass Therapeutics, Inc. (CMPX)vs › | $179.75M | 0.00% | 50.00% | 25.00% | 16.67% |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $179.26M | 0.65% | 0.33% | 50.16% | 60.13% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 99.20% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |